Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN Imprimir: 0893-9675
ISSN En Línea: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v18.i1-2.20
pages 1-18

Historical Perspective of Cell-Cell Fusion in Cancer Initiation and Progression

George E. Parris
Tufts University School of Medicine, Center of Cancer Systems Biology, 736 Cambridge Street, Boston, Massachusetts


This review discusses the topic of cell-cell fusion as it related to cancer causation, progression and metastasis. The relevant time period is over a century of research and analysis from the observation and hypothesis of Theodor Boveri in circa 1902 to the most recent publications in 2012. There are three main intertwined thrusts in this history: (i) progress in our overall understanding of cancer and the relative importance of mutations and aneuploidy; (ii) evidence that cell-cell fusion occurs and leads to aneuploidy in somatic cells, especially that cell-cell fusion allows rapid evolution of cancer cells that, most importantly, acquire a repertoire of traits from bone marrow-derived cells that facilitate metastasis; and (iii) evidence that viruses catalyze cell-cell fusion and that aneuploidy evolving from the hybrid cells is an important if not the principal basis for the association of viruses with certain cancers. There have been many competing hypotheses concerning all aspects of cancer development during this time period. Overall, the cell-cell fusion hypothesis has never gained preeminence. As a result, it has gone through long periods of obscurity only to be re-discovered because new supportive data appeared. Technical advances (especially in our ability to sequence genomes and establish the evolution of cell clones through cytogenetics) have recently made tools available that could help elucidate the role of cell-cell fusion, aneuploidy and viruses in cancer. Evidence seems to be increasing in support of the ideas stated by Boveri a century ago.

Articles with similar content:

Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 5-6
Devasis Chatterjee, Austin DeChalus, Peter J. Quesenberry, Andrew R. Mendelsohn, Joseph F. Renzulli II, Justin Q. Wang, Giovanni Camussi, Devin N. Chatterjee, Atsushi Mizokami, Evan T. Keller
CD20 and Its Antibodies: Past, Present, and Future
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 1-2
Robert J. Oldham, Mark S. Cragg, Kirstie L.S. Cleary
Targeting of EPH Receptor Tyrosine Kinases for Anticancer Therapy
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 2
Martin Lackmann, Eva Nievergall, Thomas Saunders
Exosome Release by Primary B Cells
Critical Reviews™ in Immunology, Vol.29, 2009, issue 3
Alexander McLellan
Cancer and Cancer Stem Cells: New Molecular Perspectives
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 1
Onur Sahin, Gokce Ceren Kuscu, Gulperi Oktem, Elif Tunc, Funda Cagirir Dindaroglu, Cevik Gurel, Ismet Hortu, Gizem Inetas, Aylin Buhur